ABIOMED, Inc.
May 2, 2013
PDF

Abiomed Announces Fourth Quarter GAAP EPS of $0.09 on Record Revenue and Patients Supported

Full Year Revenue Exceeds Management Guidance

DANVERS, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported fourth quarter fiscal 2013 revenue of $43.7 million, up 17% compared to revenue of $37.3 million in the same period of fiscal 2012, and fourth quarter fiscal 2013 GAAP net income of $3.7 million or $0.09 per diluted share, compared to GAAP net income of $2.6 million or $0.06 per diluted share in the prior year. For the full fiscal year 2013, total revenue was $158.1 million, up 25% compared to $126.4 million for fiscal year 2012, and GAAP net income was $15.0 million or $0.37 per share, compared to GAAP net income of $1.5 million or $0.04 per diluted share in the prior year.

Financial and operating highlights during the fourth quarter of fiscal 2013 include the following:

"We are proud to report another record quarter and record fiscal year in both number of patients supported and total revenue," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. "Our company has transformed into a resilient commercial organization, that is profitable, debt free and expanding the number of exclusive regulatory approvals, breakthrough innovative products and geographical reach."

Based on current expectations, Abiomed expects fiscal year 2014 revenue to be in the range of $180 million to $185 million. Worldwide Impella revenue is forecasted to increase by approximately 20%. GAAP operating margin rate for the full fiscal year is expected to be in the range of 7% to 8% of revenue, including estimated legal costs of approximately $6.0 million to $8.0 million associated with the Department of Justice and shareholder matters.

The Company will host a conference call to discuss the fourth quarter and full fiscal year 2013 results today at 8:00 a.m. ET with Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer; and Susan V. Lisa, Senior Director of Investor Relations and Corporate Development.

To listen to the call live, please tune into the webcast via http://investor.abiomed.com or dial (877) 638-9567; the international number is (253) 237-1032. A replay of this conference call will be available beginning at 11 a.m. ET May 2, 2013 through 11:59 p.m. ET on May 10, 2013. The replay phone number is (855) 859-2056; the international number is (404) 537-3406. The replay access code is 36674557.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Abiomed, Inc. and Subsidiaries
Consolidated Balance Sheets
(Unaudited)
(in thousands, except share data)
   
 March 31, 
  2013 2012
   
ASSETS    
Current assets:    
Cash and cash equivalents $ 9,451 $ 5,990
Short-term marketable securities  67,256  71,233
Accounts receivable, net   22,946  20,458
Inventories   14,930  11,142
Prepaid expenses and other current assets  2,022  1,716
Total current assets  116,605  110,539
Long-term marketable securities  11,406  -- 
Property and equipment, net  6,549  6,378
Intangible assets, net  --   115
Goodwill  35,410  36,846
Other long-term assets  29  33
Total assets $ 169,999 $ 153,911
LIABILITIES AND STOCKHOLDERS' EQUITY  
Current liabilities:    
Accounts payable  $ 7,696 $ 6,910
Accrued expenses  15,162  12,480
Deferred revenue  4,198  3,025
Total current liabilities  27,056  22,415
Long-term deferred tax liability  5,555  4,799
Other long-term liabilities  308  400
Total liabilities  32,919  27,614
Commitments and contingencies  
Stockholders' equity:    
Class B Preferred Stock, $.01 par value  --   -- 
Authorized - 1,000,000 shares; Issued and outstanding - none  
Common stock, $.01 par value  397  393
Authorized - 100,000,000 shares; Issued - 39,788,383 shares at March 31, 2013 and 39,323,708 shares at March 31, 2012; Outstanding - 38,601,384 shares at March 31, 2013 and 39,272,754 shares
Additional paid in capital  414,810  401,771
Accumulated deficit  (258,261)  (273,275)
Treasury stock at cost - 1,186,999 shares at March 31, 2013 and 50,954 shares at March 31, 2012  (16,129)  (827)
Accumulated other comprehensive loss  (3,737)  (1,765)
Total stockholders' equity  137,080  126,297
Total liabilities and stockholders' equity $ 169,999  $ 153,911
 
 
Abiomed, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
(in thousands, except share data)
         
 Three Months Ended Year Ended 
 March 31, March 31, 
   2013 2012 2013 2012
Revenue:        
Product revenue $ 43,536 $ 37,237  $ 157,614 $ 125,286
Funded research and development 138 107  510  1,089
  43,674 37,344  158,124  126,375
Costs and expenses:      
Cost of product revenue 8,826 6,786  31,596  24,507
Research and development  6,822 7,236  25,647  27,159
Selling, general and administrative  23,894 20,028  84,227  71,711
Amortization of intangible assets  -- 352  111  1,478
  39,542 34,402  141,581  124,855
Income from operations 4,132 2,942  16,543  1,520
Other income (expense):      
Investment (expense) income, net (7) 1  (7)  (3)
Gain on settlement of investment  --  --  --   1,017
Other income (expense), net 15 (15)  326  9
  8 (14)  319  1,023
Income before provision for income taxes 4,140 2,928  16,862  2,543
Income tax provision 398 361  1,848  1,048
Net income $ 3,742 $ 2,567  $ 15,014 $ 1,495
         
Basic net income per share $ 0.10 $ 0.07 $ 0.38 $ 0.04
Basic weighted average shares outstanding 38,445 38,840 39,113 37,159
         
Diluted net income per share $ 0.09 $ 0.06 $ 0.37 $ 0.04
Diluted weighted average shares outstanding 39,824 41,251 41,052 40,172
CONTACT: Susie Lisa, CFA

         Senior Director, Investor Relations and Corporate Development

         978-646-1590

         slisa@abiomed.com

         

         Aimee Genzler

         Corporate Communications Manager

         978-646-1553

         ir@abiomed.com